Bellus Health and Auven Therapeutics explore sale of orphan drug KIACTA
Bellus Health Inc and private equity firm Auven Therapeutics have engaged a financial adviser to explore the sale of KIACTA, an orphan drug nearing completion of its Phase III trial as a treatment for AA amyloidosis. Auven acquired the worldwide rights to KIACTA from the Laval, Québec-based Bellus Health in 2010. Operating from the British Virgin Islands, Auven invests in the healthcare industry. The firm said it had received indications of strong interest from prospective buyers of KIACTA. Bellus Health is a drug development company focused on rare diseases.
8 May 2014•6 mins read
